AU2010334428B2 - Vaccine compositions - Google Patents

Vaccine compositions Download PDF

Info

Publication number
AU2010334428B2
AU2010334428B2 AU2010334428A AU2010334428A AU2010334428B2 AU 2010334428 B2 AU2010334428 B2 AU 2010334428B2 AU 2010334428 A AU2010334428 A AU 2010334428A AU 2010334428 A AU2010334428 A AU 2010334428A AU 2010334428 B2 AU2010334428 B2 AU 2010334428B2
Authority
AU
Australia
Prior art keywords
klh
composition
peptide
linker
liq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010334428A
Other languages
English (en)
Other versions
AU2010334428A1 (en
Inventor
Syed Saleem Ahmed
John Joseph Buckley Iii
Lavinia Marina Lewis
Brandi Rae Osborne
Sandipan Sinha
Jennifer Marie Thorn
Ferhana Zaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of AU2010334428A1 publication Critical patent/AU2010334428A1/en
Application granted granted Critical
Publication of AU2010334428B2 publication Critical patent/AU2010334428B2/en
Priority to AU2015215852A priority Critical patent/AU2015215852A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010334428A 2009-12-22 2010-12-08 Vaccine compositions Ceased AU2010334428B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015215852A AU2015215852A1 (en) 2009-12-22 2015-08-19 Vaccine compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
US61/289,083 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015215852A Division AU2015215852A1 (en) 2009-12-22 2015-08-19 Vaccine compositions

Publications (2)

Publication Number Publication Date
AU2010334428A1 AU2010334428A1 (en) 2012-07-05
AU2010334428B2 true AU2010334428B2 (en) 2015-05-21

Family

ID=43797591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010334428A Ceased AU2010334428B2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Country Status (13)

Country Link
US (3) US20130034573A1 (enExample)
EP (2) EP2515934B1 (enExample)
JP (2) JP6007105B2 (enExample)
KR (1) KR20120120185A (enExample)
CN (2) CN107412754A (enExample)
AU (1) AU2010334428B2 (enExample)
CA (1) CA2785585A1 (enExample)
IL (1) IL220308A0 (enExample)
MX (1) MX337070B (enExample)
NZ (2) NZ629256A (enExample)
RU (1) RU2581020C2 (enExample)
SG (2) SG181628A1 (enExample)
WO (1) WO2011077309A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2536399T (lt) * 2010-02-21 2020-03-10 Bayer Healthcare Llc Biomolekulių aktyvinimo ir konjugavimo būdas
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN112088017B (zh) * 2018-07-19 2023-11-21 赫利世弥斯株式会社 用于裸脱氧核糖核酸基因疗法的经冷冻干燥的药剂学组合物
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1475100A1 (en) * 2002-02-14 2004-11-10 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
WO2007056061A2 (en) * 2005-11-02 2007-05-18 Duke University Concurrent chemotherapy and immunotherapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (enExample) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69025946T2 (de) * 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
DE69821246T2 (de) * 1997-07-31 2004-11-04 Metra Biosystems, Inc., Mountain View Testverfahren für collagenpeptid
DE69840508D1 (de) * 1997-08-27 2009-03-12 Childrens Hosp Medical Center Molekular-mimetika von meningokokkus b epitopen
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
DE60334460D1 (de) * 2002-08-14 2010-11-18 Mitsubishi Chem Medience Corp Antikörper spezifisch für das tau-protein des zentralen nervensystems
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
MXPA05014155A (es) * 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
PT1684719E (pt) * 2003-11-14 2012-02-03 Baxter Int Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
AU2006284248B2 (en) * 2005-05-24 2010-10-07 Neovacs A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFalpha and a carrier protein
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1475100A1 (en) * 2002-02-14 2004-11-10 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
WO2007056061A2 (en) * 2005-11-02 2007-05-18 Duke University Concurrent chemotherapy and immunotherapy

Also Published As

Publication number Publication date
US20150087815A1 (en) 2015-03-26
JP2015180667A (ja) 2015-10-15
KR20120120185A (ko) 2012-11-01
IL220308A0 (en) 2012-07-31
US20130034573A1 (en) 2013-02-07
MX337070B (es) 2016-02-11
SG10201408505SA (en) 2015-02-27
CN107412754A (zh) 2017-12-01
EP2515934A2 (en) 2012-10-31
RU2012131162A (ru) 2014-01-27
JP6146927B2 (ja) 2017-06-14
JP6007105B2 (ja) 2016-10-12
CA2785585A1 (en) 2011-06-30
NZ600978A (en) 2014-08-29
JP2013515049A (ja) 2013-05-02
MX2012007283A (es) 2012-07-30
CN102762224A (zh) 2012-10-31
WO2011077309A2 (en) 2011-06-30
EP3257525A2 (en) 2017-12-20
EP3257525A3 (en) 2018-02-28
NZ629256A (en) 2016-02-26
RU2581020C2 (ru) 2016-04-10
WO2011077309A3 (en) 2011-10-06
SG181628A1 (en) 2012-07-30
US20190365886A1 (en) 2019-12-05
AU2010334428A1 (en) 2012-07-05
EP2515934B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
US20190365886A1 (en) Vaccine compositions
JP7059095B2 (ja) コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用
AU2016295566B2 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
TWI565713B (zh) 蛋白基質疫苗以及該疫苗的製造與使用方法
JP2021505589A (ja) 肺炎球菌多糖類−タンパク質コンジュゲートを含む組成物およびその使用方法
CN103826656B (zh) 金黄色葡萄球菌抗原的稳定的免疫原性组合物
KR100452475B1 (ko) 변형된메닝고코컬다당류접합백신
TW201110977A (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SG178169A1 (en) Immunogenic composition comprising antigenic s. aureus proteins
CA2674269A1 (en) Three component glycolipopeptides
KR102183569B1 (ko) 박테리아성 백신 및 그의 제조방법
KR20120104178A (ko) 면역원성이 개선된 단백질 매트릭스 백신
US20240325564A1 (en) Pharmaceutical composition containing anti-trop2 antibody drug conjugate and its application
US20040191252A1 (en) Therapeutic uses of complement receptor 2
AU2015215852A1 (en) Vaccine compositions
HK40117919A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025021712A1 (en) Immunogenic composition
HK40074440B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1147285A (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
HK1229726B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired